PR98564

FRANKFURT, Germany Nov. 1, 2022 /PRNewswire=KYODO JBN/ --

- Lo.Li. Pharma International to unveil an innovative new product at CPHI

Frankfurt, which has already gained the interest of numerous distribution

partners. Pervistop[R] promises to be an extremely effective tool in the

management of an exceedingly unpredictable disease.

Lo.Li. Pharma International announces the pre-launch of a new, highly

anticipated product at CPHI 2022, fulfilling a latent unmet clinical need for

patients with the Human Papilloma Virus (HPV). As the largest pharma industry

event worldwide, CPHI Frankfurt will allow thousands of participants to have a

first look at this innovative product, whose exclusive formula helps to

counteract the signs, symptoms, and persistence of HPV.

According to the National Foundation for Infectious Diseases, about 80% of

sexually active women and men are infected with HPV at some point in their

lives. HPV is the most common sexually transmitted infection worldwide, and it

is known to cause certain cancers and genital warts.

"We know that 95% of cervical cancer is due to the human papillomavirus, and

cervical cancer is almost entirely preventable," said Samanta De Filippi,

General Manager of Lo.Li. Pharma International. "Pervistop[R] provides a true

alternative to eradicating the root problem of HPV persistence, which can

unpredictably evolve into cancer".

During this pre-launch phase, Lo.Li. Pharma International will be focusing on

building strategic partnerships with companies who are committed to providing

innovative options in their local market, and who are already well-versed in

the Gynecological therapeutic area.

De Filippi said, "Having already launched Pervistop[R] in the Italian market,

we know the difficulties HPV patients face and the hopelessness women feel when

they have a persistent HPV diagnosis. The Lo.Li. Pharma Group was the first to

offer an EGCG-based supplement to HPV patients in Italy, and our partners can

be the first and only in their markets, too."

Contact Raffaele Secchi, who is leading the project, to learn more about

Pervistop [R] and global partnership opportunities:

Raffaele Secchi

Business Development Manager

r.secchi@lolipharmainternational.com

About Lo.Li. Pharma International

It's not easy to stay competitive in crowded markets and innovating through

internal product development can be both expensive and risky. What's more, many

nutraceutical and medical device development companies don't invest in robust

clinical research, which could negatively impact market success of in-licensed

products. Lo.Li. Pharma International is a branch of Lo.Li. Pharma Srl, a

growing healthcare company based in Rome, dedicated to the research,

development and distribution of innovative, clinically tested and proven

Medical Devices and Functional Dietary Supplements. As world-renowned experts

in inositol and nutraceutical basic science and research, Lo.Li. Pharma

International is committed to supporting our Partners through equitable,

exclusive distribution agreements, while sharing the scientific know-how and

marketing strategies, which are needed to be successful. To learn more, go to:

www.lolipharmainternational.com　

Media Contact: Micaela Sadowski

Lo.Li. Pharma International

m.sadowski@lolipharmainternational.com

t. +39 06.88379670 Extension 33

Photo - https://mma.prnewswire.com/media/1934073/Pervistop.jpg

Logo -  https://mma.prnewswire.com/media/1934074/LoLi_Pharma_Logo.jpg

SOURCE Lo.Li. Pharma International